Interventional Cardiology

CHOICE- Carotid artery stenting and embolic protection systems
A prospective, non-randomized, study evaluating outcomes of carotid artery stenting performed using embolic protection systems.

• Patients who require carotid stents and/or embolic protection systems
• Follow-up with within 24 hours and 30 days post-procedure
• The primary investigator is James Rossen, M.D.
• The study coordinator is Amy Ollinger, RN, BSN (319) 353-6675
  

CORAL - Renal Artery Stenting for Hypertension
Cardiovascular Outcomes in Renal Atherosclerotic lesions.

• This study is designed to test the hypothesis that stenting renal artery stenoses in patients with systolic hypertension reduces the incidence of adverse cardiovascular and renal events compared with medical therapy alone.
• Patients will be randomized after angiography to either medical therapy or medical therapy with renal artery stenting and be closely monitored for blood pressure control and management of other risk factors from 3-to-5 years.
• The primary investigator is James Rossen, MD
• The study coordinator is Ronda Wilson, RN, BSN (319)-353-6675
  

OSIRIS – Adult Mesenchymal Stem Cell Infusion Following Acute Myocardial Infarction
Phase II randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of PROCHYMAL® (Ex-Vivo cultured adult mesenchymal stem cells) intravenous infusion following first acute myocardial infarction. Full Text View.

• The primary objective is to establish the safety and efficacy of PROCHYMAL® following first acute Myocardial infarction.
• Subjects must have experienced a first acute myocardial infarction within 7 days prior to randomization and drug infusion and have a baseline left ventricular ejection fraction of 20-45%.
• Subjects will be randomized to the PROCHYMAL® group or placebo group
• Periodic clinic visit follow-up for 24 months.
• The primary investigator is Phillip A Horwitz, MD

The study coordinator is Amy Ollinger, RN, BSN (319)353-6675

PFO ACCESS REGISTRY- PFO closure
Treatment with the AMPLATZER PFO Occluder in subjects with a patent foramen ovale (PFO) who have already experienced at least two unexplained strokes and who have failed conventional drug therapy.

• Patients must be on antiplatelet or anticoagulant therapy
• Patients will be on antiplatelet / anticoagulation therapy for 6 months post procedure.
• Follow-up visits in the Cardiology Clinic at 6 months and 1 year
• The primary investigator is Phillip A. Horwitz, M. D.
• The study coordinator is Ronda Wilson, RN, BSN (319) 353-6675
  

PREDICT – Identification of Gene Expression Patterns in Circulating Cells that Predict the Presence of Coronary Artery Disease
Primary objective is to identify whether white blood cell and platelet genes are expressed differently in individuals with clinically significant coronary artery disease and to use those genes to develop a genomic blood test for coronary artery disease. Full Text View.

• One time blood draw
• Phone call follow-up at 6 months and one year.
• The primary investigator is Phillip A. Horwitz, M.D.
• The study coordinator is Amy Ollinger, RN, BSN (319) 353-667
  

PREMIUM - PFO Closure for Migraine Headaches
Randomized, controlled, double-blind study to evaluate incidence of headache reduction in subjects with migraine and PFO (patent foramen ovale) using the AMPLATZER PFO Occluder compared to medical management over a 12-month period.

• Subjects with 6-14 migraine headache days per month that have been unresponsive to two or more preventive headache medications.
• Subjects will be randomized to the device group or placebo procedure group.
• Follow-up with neurologist once a month for 6 months, then every other month until 12 months post-procedure.
• Follow-up with cardiologist 1 month post-procedure.
• The primary investigator is Phillip A. Horwitz, M.D.
• The study coordinator is Ronda Wilson, RN, BSN (319)-353-6675
  

SOLSTICE – Study of Losmapimod Treatment on Inflammation and Infarct Size
Randomized, double-blind, placebo-controlled study to evaluate the safety of 12 weeks of dosing with GW856553 and its effects on inflammatory markers, infarct size, and cardiac function in subjects with myocardial infarction without ST segment elevation.

• Subjects diagnosed with non ST elevation myocardial infarction within 12 hours of enrollment.
• Subjects will be randomized to losmapimod group or placebo group
• Periodic follow-up visits for 6 months
• Primary investigator is Phillip A. Horwitz, M. D.
• The study coordinator is Amy Ollinger, RN, BSN (319)353-6675
  

Timi Solid – Darapladib versus Placebo
Clinical outcomes study of Darapladib versus placebo in subjects following acute coronary syndrome to compare the incidence of major adverse cardiovascular events (MACE).

• Subjects hospitalized with ACS (unstable angina, Non-ST segment elevation MI or ST segment elevation MI
• Subjects will be randomized to Darapladib group or placebo group
• Periodic follow-up visits at 1 month then every 3 months throughout the duration of the study.
• Primary Investigator is Phillip A. Horwitz, M.D.
• Study coordinator is Kim Miller, RN (319) 353-6675